Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial
- PMID: 14049
Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial
Abstract
A randomized double blind clinical comparison of neomycin and lactulose was performed in 33 cirrhotic patients with chronic portal-systemic encephalopathy (PSE) at seven cooperating hospitals. In order to maintain double blindness, sorbitol syrup was used as a control solution along with neomycin and was compared with lactulose syrup and placebo tablets in a double drug protocol. Twenty-nine patients were studied in a crossover investigation in which each received both therapeutic regimens preceded and followed by control periods. Four additional patients received one or the other agent, but did not receive both. Serial, semiquantitative assessments were made in all patients of mental status, asterixis, and the trailmaking test (TMT) and electroencephalograms (EEG) and arterial ammonia levels. Both neomycin-sorbitol and lactulose were effective in the majority of patients (83 and 90%, respectively). Each of these parameters (mental state, asterixis, TMT, EEG, and NH3) was improved significantly by neomycin-sorbitol and lactulose. The post-treatment levels for each of these measures were similar in the neomycin and lactulose-treated groups. Mean stool pH was reduced by neomycinsorbitol to 6.1 and by lactulose to 5.5. This difference was highly significant statistically. Bowel activity was similar in the two groups. Both drugs were free of toxicity. These investigations demonstrate that both lactulose and neomycin-sorbitol are effective in the treatment of chronic portal-systemic encephalopathy.
Similar articles
-
Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial.N Engl J Med. 1969 Aug 21;281(8):408-12. doi: 10.1056/NEJM196908212810803. N Engl J Med. 1969. PMID: 4894464 Clinical Trial. No abstract available.
-
Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial.Am J Dig Dis. 1978 May;23(5):398-406. doi: 10.1007/BF01072921. Am J Dig Dis. 1978. PMID: 354373 Clinical Trial.
-
Treatment of chronic portal systemic encephalopathy with bromocriptine: a double-blind controlled trial.Gastroenterology. 1979 Jun;76(6):1347-51. Gastroenterology. 1979. PMID: 374177 Clinical Trial.
-
Treatment options for hepatic encephalopathy.Pharmacotherapy. 2010 May;30(5 Pt 2):16S-21S. doi: 10.1592/phco.30.pt2.16S. Pharmacotherapy. 2010. PMID: 20412036 Review.
-
Lactulose: a review of its therapeutic and pharmacological properties with particular reference to ammonia metabolism and its mode of action of portal systemic encephalopathy.Drugs. 1972;4(1):7-48. doi: 10.2165/00003495-197204010-00003. Drugs. 1972. PMID: 4564869 Review. No abstract available.
Cited by
-
Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?Metab Brain Dis. 2013 Jun;28(2):221-5. doi: 10.1007/s11011-012-9372-0. Epub 2012 Dec 29. Metab Brain Dis. 2013. PMID: 23275147 Review.
-
Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients.Therap Adv Gastroenterol. 2016 Nov;9(6):823-835. doi: 10.1177/1756283X16658252. Epub 2016 Jul 26. Therap Adv Gastroenterol. 2016. PMID: 27803737 Free PMC article.
-
Schistosomal versus nonschistosomal variceal bleeders. Do they respond differently to selective shunt (DSRS)?Ann Surg. 1989 Apr;209(4):489-500. doi: 10.1097/00000658-198904000-00017. Ann Surg. 1989. PMID: 2784663 Free PMC article.
-
The role of functional magnetic resonance imaging of the brain in the evaluation of hepatic encephalopathy in cirrhotic patients.Clin Exp Hepatol. 2022 Dec;8(4):321-329. doi: 10.5114/ceh.2022.122296. Epub 2022 Dec 28. Clin Exp Hepatol. 2022. PMID: 36683873 Free PMC article.
-
Changes in brain size in hepatic encephalopathy: a coregistered MRI study.Metab Brain Dis. 2004 Dec;19(3-4):431-45. doi: 10.1023/b:mebr.0000043987.09022.e3. Metab Brain Dis. 2004. PMID: 15554433 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources